Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
June 2022
-
Media ReleaseNew research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equityCOVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband…
-
A shared mission to take on the “impossible” in cancer research
-
Prostate Cancer: A collective commitment to serving underserved communities
Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.
-
Media ReleaseNovartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALLIn final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than…
-
Media ReleaseNovartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trialScemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…
-
Media ReleaseNovartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III studyTreatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in…
-
Media ReleaseNew Novartis data show Piqray® effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancerBiomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
-
Media ReleaseNew CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancerKisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 OS…
-
Media ReleaseNovartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan AfricaSix African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed…
-
StatementNovartis resumes business in Ukraine
Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.
May 2022
-
Media ReleaseSandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap…
-
Media ReleaseFDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from…
Pagination
- ‹ Previous page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- …
- 152
- › Next page